Recursion Pharmaceuticals (NASDAQ:RXRX) Trading Down 2.4% - Should You Sell?

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Get Free Report) was down 2.4% during mid-day trading on Tuesday . The stock traded as low as $6.49 and last traded at $6.56. Approximately 939,641 shares were traded during trading, a decline of 84% from the average daily volume of 5,785,825 shares. The stock had previously closed at $6.72.

Wall Street Analysts Forecast Growth

A number of research firms recently weighed in on RXRX. KeyCorp decreased their price target on Recursion Pharmaceuticals from $16.00 to $12.00 and set an "overweight" rating on the stock in a research note on Thursday, July 11th. Leerink Partners lowered their price target on shares of Recursion Pharmaceuticals from $9.00 to $8.00 and set a "market perform" rating on the stock in a research note on Tuesday, September 3rd. Needham & Company LLC decreased their price objective on shares of Recursion Pharmaceuticals from $16.00 to $11.00 and set a "buy" rating on the stock in a report on Wednesday, September 4th. Finally, Jefferies Financial Group dropped their target price on shares of Recursion Pharmaceuticals from $8.00 to $6.00 and set a "hold" rating for the company in a report on Tuesday, September 3rd. Four equities research analysts have rated the stock with a hold rating and two have given a buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of "Hold" and an average price target of $9.40.

Recursion Pharmaceuticals Stock Performance

The company has a current ratio of 6.07, a quick ratio of 6.07 and a debt-to-equity ratio of 0.04. The stock's 50 day moving average is $6.69 and its 200 day moving average is $7.83. The stock has a market capitalization of $1.59 billion, a price-to-earnings ratio of -4.17 and a beta of 0.80.

Recursion Pharmaceuticals (NASDAQ:RXRX - Get Free Report) last issued its quarterly earnings data on Thursday, August 8th. The company reported ($0.40) earnings per share for the quarter, missing analysts' consensus estimates of ($0.35) by ($0.05). The business had revenue of $14.42 million for the quarter, compared to analysts' expectations of $11.96 million. Recursion Pharmaceuticals had a negative return on equity of 79.47% and a negative net margin of 755.37%. The company's revenue for the quarter was up 30.9% on a year-over-year basis. During the same period last year, the business earned ($0.38) earnings per share. On average, analysts predict that Recursion Pharmaceuticals, Inc. will post -1.58 earnings per share for the current year.

Insider Activity at Recursion Pharmaceuticals

In related news, CEO Christopher Gibson sold 30,000 shares of the business's stock in a transaction dated Wednesday, August 7th. The shares were sold at an average price of $7.10, for a total value of $213,000.00. Following the completion of the transaction, the chief executive officer now owns 758,738 shares of the company's stock, valued at approximately $5,387,039.80. The trade was a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In other Recursion Pharmaceuticals news, CEO Christopher Gibson sold 30,000 shares of the business's stock in a transaction on Wednesday, August 7th. The stock was sold at an average price of $7.10, for a total value of $213,000.00. Following the completion of the transaction, the chief executive officer now directly owns 758,738 shares in the company, valued at approximately $5,387,039.80. The trade was a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CFO Michael Secora sold 15,000 shares of the firm's stock in a transaction on Tuesday, October 8th. The stock was sold at an average price of $6.32, for a total value of $94,800.00. Following the sale, the chief financial officer now owns 1,426,506 shares in the company, valued at $9,015,517.92. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 201,682 shares of company stock valued at $1,353,652 over the last quarter. Insiders own 15.75% of the company's stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the stock. Exchange Traded Concepts LLC increased its position in Recursion Pharmaceuticals by 24.9% during the third quarter. Exchange Traded Concepts LLC now owns 25,182 shares of the company's stock worth $166,000 after purchasing an additional 5,021 shares during the last quarter. San Luis Wealth Advisors LLC purchased a new position in shares of Recursion Pharmaceuticals in the 3rd quarter worth $69,000. Green Alpha Advisors LLC grew its position in Recursion Pharmaceuticals by 2.9% during the third quarter. Green Alpha Advisors LLC now owns 64,799 shares of the company's stock valued at $427,000 after acquiring an additional 1,800 shares during the period. Handelsbanken Fonder AB increased its stake in Recursion Pharmaceuticals by 33.4% during the third quarter. Handelsbanken Fonder AB now owns 69,500 shares of the company's stock worth $458,000 after acquiring an additional 17,400 shares during the last quarter. Finally, SG Americas Securities LLC raised its holdings in shares of Recursion Pharmaceuticals by 249.0% in the 3rd quarter. SG Americas Securities LLC now owns 89,325 shares of the company's stock worth $589,000 after purchasing an additional 63,727 shares during the period. Institutional investors and hedge funds own 89.06% of the company's stock.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.